---
stable_id: R-HSA-9652264
display_name: ERBB2 binds TKIs
species: Homo sapiens
summary: ERBB2 can bind to and be inhibited by the following tyrosine kinase inhibitors
  (TKIs):<br>lapatinib (Xia et al. 2002, Wood et al. 2004)<br>neratinib (Rabindran
  et al. 2004)<br>afatinib (Li et al. 2008)<br>AZ5104 (Hanker et al. 2017)<br>tesevatinib
  (Gendreau et al. 2007)<br>canertinib (Nelson and Fry 2001)<br>sapitinib (Hickinson
  et al. 2010)<br>CP-724714 (Jani et al. 2007)<br>AEE788 (Traxler et al. 2014). Tyrosine
  kinase inhibitors do not prevent ERBB2 heterodimerization, but intefere with its
  kinase activity.<br>The following tyrosine kinase inhibitors were shown to be especially
  effective against overexpressed ERBB2 and to inhibit kinase activity of ERBB2 homodimers:<br>afatinib
  (Rabindran et al. 2004)<br>neratinib (Rabindran et al. 2004)<br>lapatinib (Rabindran
  et al. 2004).
---

# ERBB2 binds TKIs
**Reactome ID:** [R-HSA-9652264](https://reactome.org/content/detail/R-HSA-9652264)
**Species:** Homo sapiens

## Summary

ERBB2 can bind to and be inhibited by the following tyrosine kinase inhibitors (TKIs):<br>lapatinib (Xia et al. 2002, Wood et al. 2004)<br>neratinib (Rabindran et al. 2004)<br>afatinib (Li et al. 2008)<br>AZ5104 (Hanker et al. 2017)<br>tesevatinib (Gendreau et al. 2007)<br>canertinib (Nelson and Fry 2001)<br>sapitinib (Hickinson et al. 2010)<br>CP-724714 (Jani et al. 2007)<br>AEE788 (Traxler et al. 2014). Tyrosine kinase inhibitors do not prevent ERBB2 heterodimerization, but intefere with its kinase activity.<br>The following tyrosine kinase inhibitors were shown to be especially effective against overexpressed ERBB2 and to inhibit kinase activity of ERBB2 homodimers:<br>afatinib (Rabindran et al. 2004)<br>neratinib (Rabindran et al. 2004)<br>lapatinib (Rabindran et al. 2004).
